"These cut-backs will have an impact on MS. One of the great unmet needs in MS is better symptomatic treatments to treat spasticity, cognitive impairment, fatigue, pain, depression, bladder & bowel problems, sexual dysfunction, walking difficulties, incoordination, tremor, jumpy vision, seizures, flexor spasms, etc."
"Big Pharma pulling out of neuroscience or downsizing will affect all these areas. We need to lobby industry to reverse this trend. I always maintain that the market for symptomatic MS therapies is as large if not bigger than the DMT market. The reason for this is that symptomatic therapies that work in MS are likely to work in other neurological disorders."